	US 11,850,223 B2
	Methods of treatment of cholestatic diseases
Remy Hanf, Lille (FR)
Assigned to Genfit, Loos (FR)
Filed by Genfit, Loos (FR)
Filed on Jun. 20, 2023, as Appl. No. 18/212,008.
Application 18/212,008 is a continuation of application No. 17/533,767, filed on Nov. 23, 2021.
Application 17/533,767 is a continuation of application No. 16/894,110, filed on Jun. 5, 2020, granted, now 11,331,292, issued on May 17, 2022.
Application 16/894,110 is a continuation in part of application No. 16/090,415, granted, now 11,185,519, issued on Nov. 30, 2021, previously published as PCT/EP2017/057634, filed on Mar. 30, 2017.
Claims priority of application No. 16305381 (EP), filed on Mar. 31, 2016.
Prior Publication US 2023/0330048 A1, Oct. 19, 2023
Int. Cl. A61K 31/192 (2006.01); A61P 37/06 (2006.01); A61K 45/06 (2006.01)

CPC A61K 31/192 (2013.01) [A61K 45/06 (2013.01); A61P 37/06 (2018.01)]

10 Claims

1. A method for treating pruritus associated to cholestatic disease in a subject having primary biliary cholangitis (PBC) with pruritus, the method comprising orally administering a composition comprising elafibranor or a pharmaceutically acceptable salt of elafibranor at a dose between 70 mg and 130 mg per administration to said subject.